AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06685653 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adebrelimab+RGL-270
Description: Drug: Adebrelimab Adebrelimab is a programmed death-ligand 1 antibody.~Drug: RGL-270 RGL-270 is a mRNA tumor vaccines
Study NCT06685653 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adebrelimab+RGL-270/single RGL-270
Description: Drug: Adebrelimab Adebrelimab is a programmed death-ligand 1 antibody.~Drug: RGL-270 RGL-270 is a mRNA tumor vaccines
Study NCT06685081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine was injected in dose of 0.25 µg/kg
Study NCT06685081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine was injected in dose of 0.5 µg/kg
Study NCT06685081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine was injected in dose of 0.75 µg/kg
Study NCT06685081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine was injected in dose of 1 µg/kg
Study NCT05493423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V Needle AV Fistula Set
Description: Hemotek Medical Inc. has developed the V Needle, a new AV fistula set for hemodialysis designed to reduce patient risk from exsanguination-related injury or death during therapy. In the event of complete dislodgement of the V Needle from the arm during use, the V Needle is designed to activate, creating high line pressure designed to generate an automated dialysis machine blood pump shut down.
Study NCT06685081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine and triamcinolone
Description: 2 ml of 1.5% lidocaine and 2 ml of triamcinolone was mixed and provided to all patients as epidural injection
Study NCT06684795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG001 prior to surgery
Description: Patients will receive a single intravenous injection of 36 mg FG001 administered the day before surgery.
Study NCT06684210 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intercostal plane block of the external oblique muscle
Description: Under ultrasound guidance, a single dose of 0.25% ropivacaine 20ml was given for bilateral intercostal muscle plane block of external oblique muscles
Study NCT06683430 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Potassium, Low Sodium Diet
Description: Daily intake of 3500 mg K and 1500 mg Na for 14 days.
Study NCT06683430 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standard Diet
Description: Daily intake of 1700 mg K and 2000 mg Na for 14 days.
Study NCT06684392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Subjects will train only inspiratory muscle strength if they do not achieve VP or definitive disconnection of MV, and, when they already achieve these VP or definitive disconnection, the new EMI regimen that combines strength and resistance training will begin to be applied. Inspiratory muscle training guideline (EMI). On the day that, according to the EMI guideline, the Pimax evaluation corresponds, the training time will be replaced by the evaluation to avoid overloading the subjects with ventilatory work, training them only once a day.
Study NCT06682026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: listening to music or chatting
Description: Written consent will be obtained from the patients just before they enter the procedure, and Personal Information Forms and the State Anxiety Inventory (STAI) will be applied to all participants.~Women in the experimental group will be asked to listen to a lively music of their own choosing during the mammography, or for those who do not want music, their attention will be drawn in a different direction by chatting.~At the end of the procedure, the Visual Acuity Scale (VAS) pain scale and the State Anxiety Inventory (STAI) will be applied to both groups.
Study NCT06682936 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ambulatory chest drain and talc pleurodesis
Description: a chest drain will be inserted, fluid drained and medical talc instilled on an ambulatory basis
Study NCT06368986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4011499
Description: VH4011499 administered in fasted or fed conditions.
Study NCT06685367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acura AKI
Description: When the AI algorithm (Acura AKI) identifies a high-risk AKI patient, nephrologists and ICU pharmacists will receive an alert message. Upon receiving the alert, they will review the patient's electronic health record and make treatment suggestions based on AKI bundle care protocols. They will also coordinate with the patient's primary care team to ensure that the recommendations are implemented
Study NCT06683417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation Aid
Description: The tablet-based VestAid system was developed to repair, restore and maintain vestibular-ocular function that is impaired in patients post-mTBI.~Each participant\&amp;#39;s treating physical therapist will develop their own personalized exercise prescription. The physical therapist will be asked to recommend that the patients complete a home exercise program at least 2-3 times per day for 6 weeks. The exercise prescription will be placed on the VestAid by the physical therapist for the patient to follow. The patient is not able to modify the exercise, only the physical therapist can modify the exercises. Exercises will be modified based on patient\&amp;#39;s response and symptom reports. The physical therapist and study coordinator will receive an alert on the VestAid online dashboard if the patient\&amp;#39;s symptoms are greater than or equal to 8/10.
Study NCT06683417 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care vestibular rehabilitation
Description: Vestibular rehabilitation to include gaze stabilization exercises, optokinetic training, smooth pursuits and saccades
Study NCT06683885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone
Description: For non GCB type: Rituximab, 375mg/m2, QD, D1,8,15(the first cycle), d1(Starting from the second cycle), ivgtt; Compound Cyclophosphamide Tablets, 50mg:50mg BID, P.O.; Obutinib, 150mg, QD, P.O.; Prednisone, 60mg, QD D1-7, P.O. Every 21 days is a cycle, and the efficacy is evaluated every 2 cycles. Obutinib maintain treatment for 6 months. Obutinib, 150mg, QD, P.O. After 6 cycles of initial treatment, the efficacy was evaluated.~For GCB type: Rituximab, 375mg/m2, QD, D1,8,15(the first cycle), d1(Starting from the second cycle), ivgtt; Compound Cyclophosphamide Tablets, 50mg:50mg BID, P.O.; Decitabine, 10mg, QD，D1-5, ivgtt; Prednisone, 60mg, QD D1-7, P.O. Every 21 days is a cycle, and the efficacy is evaluated every 2 cycles. Decitabine maintenance treatment for 4 cycles, 21 days per cycle. Decitabine, 10mg, QD，D1-5, ivgtt. Evaluate the efficacy after 6 cycles of treatment.
Study NCT06683716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training in presence of the instructor
Description: The instructor gives the trainee instructions for the examination while he/she is present in the examination room.
Study NCT05458375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol vaginal cream
Description: Insert pea-sized amount of vaginal estradiol cream into vagina nightly for first two weeks and then twice weekly thereafter.
Study NCT06683716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedically training by an instructor
Description: The trainer gives instructions to the trainee through a telemedical connection to the examiner using SmartGlasses
Study NCT05618119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [18F]MC225
Description: \[18F\]MC225 PET scan
Study NCT05544513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate 3 days week
Description: Participants will receive one ferrous sulfate capsule (120 mg of elemental iron) on Mondays, Wednesdays and Fridays
Study NCT05544513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate daily
Description: Participants will receive one ferrous sulfate (120 mg of elemental iron) capsule daily (except on Sundays)
Study NCT05544513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate higher concentration
Description: Participants will receive one ferrous sulfate capsule (240mg of elemental iron) on Mondays, Wednesdays and fridays
Study NCT06355310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Participants will take a 10 mg oral tablet of empagliflozin, an orally-active inhibitor of sodium-glucose co-transporter 2 (SGLT2)
Study NCT06355310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Participants will take an identical appearing oral tablet with zero active ingredient.
Study NCT04183413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DSD
Description: This intervention consist of three Differentiated Service Delivery Models in which stable clients can be enrolled. The fast-track model gives preferential treatment to enrolled clients. Clients arrive at clinics, usually early in the morning, and can see the nurse as well as collect their medication without queuing. This model mainly targets the working population. The facility-based treatment clubs consist of bimonthly meetings where clients meet in groups of approximately 20 members. They receive health counselling, risk factor screening and medication prescription. This model mainly targets clients living close to the facility. The community advisory groups consist of groups of up to six clients. Groups are equipped with a point of care blood pressure and blood glucose measurement devices. They take turns in collecting the medication for the entire group and meet on a monthly basis. This model targets clients in hard-to-reach areas.
Study NCT04183413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDP
Description: Community Distribution Points are set up on a monthly basis in communities linked to the clinic. Healthcare staff sets up a temporary point of contact where clients can obtain screening for diabetes and hypertension, health counselling, referral to primary or tertiary facilities, and medication.
Study NCT05708443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LL group
Description: The program will include daily sessions of 90 minutes, for a total of 14 sessions, consisting of:~1. 60 minutes on a stationary bike for the lower limbs (2 sessions per day of 30 minutes) at moderate-high intensity;~2. 30 minutes of strengthening exercises for upper limbs (biceps, pectoral, latissimus dorsi) and lower limbs (quadriceps, gluteus and hamstrings) performed free body or with the aid of weights.~All sessions will be supervised by a physiotherapist.
Study NCT05708443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L+UL group
Description: These patients will attend a rehabilitation program with daily sessions of 90 minutes, for a total of 14 sessions, consisting of:~1. 30 minutes on a stationary bike for the lower limbs (1 session of 30 minutes per day) at moderate-high intensity;~2. 30 minutes with arm-ergometer (1 daily session of 30 minutes) at moderate-high intensity;~3. 30 minutes of strengthening exercises for upper limbs (biceps, pectoral, latissimus dorsi) and lower limbs (quadriceps, gluteus and hamstrings) performed free body or with the aid of weights.~All sessions will be supervised by a physiotherapist.
Study NCT06407765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual task training
Description: Dual task training incorporates both cognitive and motor tasks. Tasks like walking and asking the patient to point towards objects, collect start from the objects hanging above the patient and asking the patient to name the objects shown to him/her. This treatment will be given for 4 weeks, 4 times a week for 40 minutes. Each task is done for 7 minutes with a 3 minutes break in between.
Study NCT06407765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual task training with backward walking
Description: This group will get both dual task training and backward walking. For dual task training same protocol as active comparator is followed. For backward walking; the patient is firstly asked to walk backward with complete physiotherapist assistance. Secondly, the patient is asked to walk for 15 m through the treatment room's hallway while holding a safety bar with the hand on the unaffected side. Third, without using a safety bar, the participants were urged to walk freely. Lastly, the participants tried to walk backwards at a reasonable pace while progressively increasing their distance travelled and speed. This treatment will be given for 4 weeks, 4 times a week for 40 minutes. Each task is done for 7 minutes with a 3 minutes break in between.
Study NCT05497427 — intervention group
Intervention type: DEVICE
Intervention: BrainCheck Assessment
Description: A computerized neurocognitive test administered via an electronic device, such as a phone, tablet or computer, that contains several assessments that will aid in establishing an individuals cognitive performance
Study NCT06001333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation
Description: Fecal microbiota transplantation will be conducted on patients using donor stool (frozen or capsulized stool) from a stool bank.
Study NCT06144632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERMOCOOL STSF Bi- Directional Navigation Catheter
Description: THERMOCOOL STSF will be used in conjunction with TRUPULSE Generator to give pulsed field (PF) ablation or radiofrequency (RF) ablation.
Study NCT06144632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRUPULSE Generator
Description: TRUPULSE Generator will be used to deliver PF/RF ablation.
Study NCT05647863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Cognitive and Sensory Treatment (F-CaST)
Description: F-CaST, a client-centered care, is a functional cognitive sensory intervention focusing on improving Executive Function (EF) and sensory modulation impairments using a modification of the Functional and Cognitive Occupational Therapy Treatment.
Study NCT04816149 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VA Standard Suicide Intervention
Description: Our active control condition is standardized and contains the elements of standard practice suicide-specific intervention delivered at the VA, which include: 1) suicide risk assessment using the CSSR-S, 2) VA Safety Planning Intervention, 3) timely referral to VA mental health outpatient care, including couples intervention (engagement will be tracked), and 4) Suicide Prevention Coordinator (SPC) follow-up contacts (which have been found to significantly reduce suicidal behavior).
Study NCT04816149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment for Relationships and Safety Together (TR&ST)
Description: TR\&ST consists of eleven 90-minute sessions delivered in three phases. During phase one, couples receive a tailored cognitive-behavioral conceptualization of suicide and relationship distress based on clinical interview, as well as psychoeducation about their bidirectional influences. They also engage in behavioral activation focused on positive couple activities, emotion regulation, distress tolerance, and conflict management strategies. In phase two, couples learn communication skills and discuss suicidal thoughts and behaviors, as well as their relationship challenges that interact with suicidal thoughts and behavior. Phase three is focused on conjoint thought challenging to shift dysfunctional cognitions related to suicide and relationship problems.
Study NCT06112730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard pulmonnary rehabilitation
Description: Undergo routine pulmonary rehabilitation without dietary intervention
Study NCT06112730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation intervention
Description: Receive personalized dietary guidelines based on indirect calorimetry assessment
Study NCT06499285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KER-050
Description: KER-050 administered subcutaneously every 4 weeks
Study NCT06499285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously every 4 weeks
Study NCT06637423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan
Description: Intravesical administration
Study NCT05302505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation-based training
Description: Based-simulation training for nurses in a simulation center : puncture of arteriovenous fistula and utilization of echograph and conversational hypnosis
Study NCT05003050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Holistic natural therapy
Study NCT05003050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pranic Healing
Description: Energy therapy
Study NCT05300802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 ml of Ringer acetate will be added to the priming solution and followed by a continuous 50 ml infusion of Ringer acetate running at 25 ml/hour.
Study NCT05300802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hcl 100 Mcg/mL Inj
Description: 1 mcg/kg diluted DEX will be added to the priming solution and followed by a continuous infusion of 50 ml Ringer acetate running at 25 ml/hour.
Study NCT05300802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hcl 100 Mcg/mL Inj
Description: 0.5 mcg/kg DEX will be added to the priming solution and followed by a continuous infusion of 0.25 mcg/kg/hour DEX diluted in 50 ml of ringer acetate running at 25 ml/hour.
Study NCT06065813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 200 mg Toripalimab intravenously every 3 weeks 3 doses of Toripalimab before operation 14 doses of Toripalimab 30 days after operation
Study NCT06065813 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional segmental radiotherapy
Description: the does of radiation will be 40-45Gy. The day of the first dose of Toripalimab and the first day of radiation must be the same day.
Study NCT06065813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: opreation
Description: The operable patients will accept radical operated in 28-42 days after the third dose of Toripalimab
Study NCT05714202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAR-200
Description: TAR-200 will be administered intravesically.
Study NCT05714202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab will be administered.
Study NCT05714202 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG Vesiculture
Description: BCG will be administered intravesically.
Study NCT06567314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivonescimab
Description: Given by PO
Study NCT05588323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Administered as an oral tablet (0.2 mg dose level only), or oral suspension (all dose levels)
Study NCT05497531 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ctDNA Blood Collection
Description: Blood collection to be obtained from peripheral vein and cancer draining vein during biopsy
Study NCT06106893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 Universal CAR-γδ T Cells
Description: Intravenous infusion of CD19 Universal CAR-γδ T Cells
Study NCT05859191 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Three extra tubes of blood will be taken at each consultation or inpatient visit when routine blood samples are taken as part of lupus monitoring.
Study NCT05711615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT05711615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection
Study NCT05711615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05711615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05711615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV
Study NCT05711615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Given PO
Study NCT05107960 — intervention group
Intervention type: DRUG
Intervention: Azilsartan (TAK-536)
Description: Azilsartan Tablets, Azilsartan Granules
Study NCT06363825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: TAE: 3-15ml iodized oil;~HAIC: Indurating arterial catheter, oxaliplatin 85mg/m\^2 D1, arterial infusion, lasting 1-2 hours (d1), LV 400mg/m\^2, arterial infusion, lasting 2-3 hours (d1), 5-Fu 400mg/m\^2, arterial infusion, lasting 3 hours (d1), and fluorouracil 2400 mg/m\^2 for 24-48h;~camrelizumab: 200mg, ivgtt, 30 min (not less than 20 min, not more than 60 min) every 3 weeks (21 days);~apatinib mesylate: 250mg, once a day, taken orally (the time of daily administration should be as much as possible), with warm water.Stop for 3 days before next cycle intervention.~Camrelizumab was given intravenously 1 day before TAE+HAIC treatment for each cycle, TAE+HAIC treatment was given on the second day, and oral apatinib was started after discharge.
Study NCT06038435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation Approach
Description: Cognitive training will be given for the selected occupation